Marqibo Kit is a drug owned by Acrotech Biopharma Llc. It is protected by 6 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 25, 2020. Details of Marqibo Kit's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7247316 | Compositions and methods for treating lymphoma |
Sep, 2020
(4 years ago) |
Expired
|
| US6723338 | Compositions and methods for treating lymphoma |
Mar, 2020
(4 years ago) |
Expired
|
| US7887836 | Compositions and methods for treating lymphoma |
Mar, 2020
(4 years ago) |
Expired
|
| US5543152 | Sphingosomes for enhanced drug delivery |
Jun, 2014
(10 years ago) |
Expired
|
| US5814335 | Sphingosomes for enhanced drug delivery |
Jun, 2014
(10 years ago) |
Expired
|
| US5741516 | Sphingosomes for enhanced drug delivery |
Jun, 2014
(10 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Marqibo Kit's patents.
Latest Legal Activities on Marqibo Kit's Patents
Given below is the list of recent legal activities going on the following patents of Marqibo Kit.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 20 Mar, 2023 | US7887836 |
| Maintenance Fee Reminder Mailed Critical | 03 Oct, 2022 | US7887836 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 28 Jan, 2019 | US7247316 |
| 11.5 yr surcharge- late pmt w/in 6 mo, Small Entity | 28 Jan, 2019 | US7247316 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 21 Aug, 2018 | US7887836 |
| Notice of Final Determination- Ineligible | 31 Mar, 2015 | US7887836 |
| Filing Receipt - Corrected | 12 Feb, 2015 | US7247316 |
| Email Notification Critical | 12 Feb, 2015 | US7247316 |
| Change in Power of Attorney (May Include Associate POA) Critical | 12 Feb, 2015 | US7247316 |
| Correspondence Address Change Critical | 11 Feb, 2015 | US7247316 |
FDA has granted several exclusivities to Marqibo Kit. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Marqibo Kit, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Marqibo Kit.
Exclusivity Information
Marqibo Kit holds 3 exclusivities. All of its exclusivities have expired in 2019. Details of Marqibo Kit's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 09, 2015 |
| Orphan Drug Exclusivity(ODE) | Aug 09, 2019 |
| Orphan Drug Exclusivity(ODE-28) | Aug 09, 2019 |
US patents provide insights into the exclusivity only within the United States, but Marqibo Kit is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Marqibo Kit's family patents as well as insights into ongoing legal events on those patents.
Marqibo Kit's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Marqibo Kit's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Sep 25, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Marqibo Kit Generic API suppliers:
Vincristine Sulfate is the generic name for the brand Marqibo Kit. 7 different companies have already filed for the generic of Marqibo Kit, with Hospira having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Marqibo Kit's generic
About Marqibo Kit
Marqibo Kit is a drug owned by Acrotech Biopharma Llc. It is used for treating Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in adults who have relapsed multiple times or progressed after multiple therapies. Marqibo Kit uses Vincristine Sulfate as an active ingredient. Marqibo Kit was launched by Acrotech in 2012.
Approval Date:
Marqibo Kit was approved by FDA for market use on 09 August, 2012.
Active Ingredient:
Marqibo Kit uses Vincristine Sulfate as the active ingredient. Check out other Drugs and Companies using Vincristine Sulfate ingredient
Treatment:
Marqibo Kit is used for treating Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in adults who have relapsed multiple times or progressed after multiple therapies.
Dosage:
Marqibo Kit is available in injectable, liposomal form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 5MG/5ML (1MG/ML) | INJECTABLE, LIPOSOMAL | Discontinued | INTRAVENOUS |